Protocol: Leveraging a demographic and health surveillance system for Covid-19 Surveillance in rural KwaZulu-Natal by Siedner, Mark J et al.
 Open Peer Review
Any reports and responses or comments on the
article can be found at the end of the article.
STUDY PROTOCOL
Protocol: Leveraging a demographic and health surveillance
 system for Covid-19 Surveillance in rural KwaZulu-Natal [version
1; peer review: awaiting peer review]
Mark J. Siedner ,       Guy Harling , Anne Derache , Theresa Smit ,
       Thandeka Khoza , Resign Gunda , Thobeka Mngomezulu , Dickman Gareta ,
       Nomathamsanqa Majozi , Eugene Ehlers , Jaco Dreyer , Siyabonga Nxumalo ,
       Njabulo Dayi , Gregory Ording-Jesperson , Nothando Ngwenya , Emily Wong ,
       Collins Iwuji , Maryam Shahmanesh , Janet Seeley , Tulio De Oliveira ,
   Thumbi Ndung'u , Willem Hanekom , Kobus Herbst1,14
Africa Health Research Institute, Durban, KwaZulu-Natal, South Africa
Massachusetts General Hospital, Boston, MA, USA
Harvard Medical School, Boston, MA, USA
Institute for Global Health, University College London, London, UK
MRC/Wits Rural Public Health & Health Transitions Research Unit (Agincourt), University of the Witwatersrand, Johannesburg, South Africa
Department of Epidemiology and Harvard Center for Population and Development Studies, Harvard T.H. Chan School of Public Health,
Boston, MA, USA
Department of Global Health and Infection, Brighton and Sussex Medical School, University of Sussex, Brighton, UK
Global Health and Development Department, London School of Hygiene & Tropical Medicine, London, UK
KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP)), School of Laboratory Medicine and Medical Sciences, University of
KwaZulu Natal, Durban, KwaZulu-Natal, South Africa
Department of Global Health, University of Washington, Seattle, USA
Division of Infection and Immunity, University College London, London, UK
HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu Natal, Durban, KwaZulu-Natal, South
Africa
Max Planck Institute for Infection Biology, Berlin, Germany
SAPRIN, South African Medical Research Council, Cape Town, South Africa
Abstract
A coordinated system of disease surveillance will be critical to effectively
control the coronavirus disease 2019 (Covid-19) pandemic. Such systems
enable rapid detection and mapping of epidemics and inform allocation of
scarce prevention and intervention resources. Although many lower- and
middle-income settings lack infrastructure for optimal disease surveillance,
health and demographic surveillance systems (HDSS) provide a unique
opportunity for epidemic monitoring. This protocol describes a surveillance
program at the Africa Health Research Institute’s Population Intervention
Platform site in northern KwaZulu-Natal. The program leverages a
longstanding HDSS in a rural, resource-limited setting with very high
prevalence of HIV and tuberculosis to perform Covid-19 surveillance. Our
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 longstanding HDSS in a rural, resource-limited setting with very high
prevalence of HIV and tuberculosis to perform Covid-19 surveillance. Our
primary aims include: describing the epidemiology of the Covid-19
epidemic in rural KwaZulu-Natal; determining the impact of the Covid-19
outbreak and non-pharmaceutical control interventions (NPI) on behaviour
and wellbeing; determining the impact of HIV and tuberculosis on Covid-19
susceptibility; and using collected data to support the local public-sector
health response.
The program involves telephone-based interviews with over 20,000
households every four months, plus a sub-study calling 750 households
every two weeks. Each call asks a household representative how the
epidemic and NPI are affecting the household and conducts a Covid-19 risk
screen for all resident members. Any individuals screening positive are
invited to a clinical screen, potential test and referral to necessary care –
conducted in-person near their home following careful risk minimization
procedures. In this protocol we report the details of our cohort design,
questionnaires, data and reporting structures, and standard operating
procedures in hopes that our project can inform similar efforts elsewhere.
Keywords
Covid-19, Surveillance, South Africa, Screening, Health and Demographic
Surveillance System
 
This article is included in the Coronavirus
 collection.(COVID-19)
Page 2 of 10
Wellcome Open Research 2020, 5:109 Last updated: 29 MAY 2020
  Kobus Herbst ( )Corresponding author: kobus.herbst@ahri.org
  : Conceptualization, Formal Analysis, Investigation, Methodology, Project Administration, Resources, Visualization,Author roles: Siedner MJ
Writing – Original Draft Preparation, Writing – Review & Editing;  : Conceptualization, Formal Analysis, Investigation, Methodology,Harling G
Visualization, Writing – Original Draft Preparation, Writing – Review & Editing;  : Project Administration, Writing – Original DraftDerache A
Preparation, Writing – Review & Editing;  : Investigation, Methodology, Project Administration, Resources, Supervision, Validation, Writing –Smit T
Review & Editing;  : Project Administration, Supervision, Writing – Review & Editing;  : Methodology, Project Administration,Khoza T Gunda R
Writing – Review & Editing;  : Methodology, Project Administration, Writing – Review & Editing;  : Data Curation,Mngomezulu T Gareta D
Resources, Software, Writing – Review & Editing;  : Project Administration, Writing – Review & Editing;  : Software, Writing –Majozi N Ehlers E
Review & Editing;  : Software, Writing – Review & Editing;  : Data Curation, Software, Writing – Review & Editing;  :Dreyer J Nxumalo S Dayi N
Software, Writing – Review & Editing;  : Data Curation, Software, Writing – Review & Editing;  : Methodology,Ording-Jesperson G Ngwenya N
Writing – Review & Editing;  : Conceptualization, Methodology, Writing – Review & Editing;  : Writing – Review & Editing; Wong E Iwuji C
: Conceptualization, Writing – Review & Editing;  : Writing – Review & Editing;  : Methodology, Resources,Shahmanesh M Seeley J De Oliveira T
Writing – Review & Editing;  : Investigation, Methodology, Validation, Writing – Review & Editing;  : Funding Acquisition,Ndung'u T Hanekom W
Supervision, Writing – Review & Editing;  : Conceptualization, Data Curation, Funding Acquisition, Investigation, Methodology, ProjectHerbst K
Administration, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing
 No competing interests were disclosed.Competing interests:
 This work was supported by the Wellcome Trust through funding for Willem Hanekom [201433]; funding for Thumbi Ndung'uGrant information:
[107752]; and a Wellcome Trust/Royal Society Sir Henry Dale fellowship to Guy Harling [210479]. Kobus Herbst is supported by the South African
Department of Science and Innovation, South African Medical Research Council and South African Population Research Infrastructure Network
(SAPRIN). Thumbi Ndung'u is supported by African Academy of Sciences (AAS)’s Alliance for Accelerating Excellence in Science in Africa (AESA)
[DEL-15-006] and the Wellcome Trust [107752]. Maryam Shahmanesh is supported by the National Institutes of Health [R01 MH114560] and the
Bill & Melinda Gates Foundation [OPP1136774, OPP1171600]. Tulio de Oliveira and Thumbi Ndung’u are supported by the National Institutes of
Health [U24 HG006941], South African Medical Research Council [MRC-RFA-UFSP-01-2013/UKZN HIVEPI] and the South African Department of
Science and Innovation (DSI). Mark J. Siedner is supported by the National Institutes of Health [R01 AI124718, R01 AG059504]. Emily Wong is
supported by the National Institutes of Health [K08 AI118538].
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
 © 2020 Siedner MJ  . This is an open access article distributed under the terms of the  ,Copyright: et al Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 Siedner MJ, Harling G, Derache A   How to cite this article: et al. Protocol: Leveraging a demographic and health surveillance system for
 Wellcome Open Research 2020,  :109 Covid-19 Surveillance in rural KwaZulu-Natal [version 1; peer review: awaiting peer review] 5
https://doi.org/10.12688/wellcomeopenres.15949.1
 29 May 2020,  :109 First published: 5 https://doi.org/10.12688/wellcomeopenres.15949.1
Page 3 of 10
Wellcome Open Research 2020, 5:109 Last updated: 29 MAY 2020
Introduction
The global emergence of the novel coronavirus, SARS-CoV-2, 
and the associated pandemic of coronavirus disease 2019 
(Covid-19) in humans, has led to substantial morbidity and 
mortality1. Models project continued risk until effective treatment 
or vaccines become available, or sufficient immunity is induced 
in the population to limit transmission2,3. The transmission and 
clinical patterns of the pandemic have been well documented in 
areas of the world where systematic data capture is in place4–7. 
However, data from low- and middle-income countries 
(LMIC) remain scant.
Multiple factors place resource-limited settings at consider-
able risk of epidemics of respiratory disease. Housing struc-
tures, large informal work sectors, high population density 
(particularly in urban slums and settlements), lack of running 
water and access to hygiene resources, and a health infrastructure 
unprepared for diseases requiring advanced medical equipment, 
all place LMICs at risk of worse outcomes than higher-income 
settings8–12. There have long been calls for strengthening pub-
lic health preparedness in such countries13,14, but despite some 
progress15, significant capacity shortfalls remain in many 
LMICs16–18. As a result, low case numbers in resource-limited 
settings should not necessarily be interpreted to reflect a lack of 
disease transmission. A coordinated system of disease surveil-
lance will be critical to effective prevention, control, and response 
to the Covid-19 epidemic in LMICs to enable rapid detection, 
transmission mapping, and non-pharmaceutical interventions, and 
to inform allocation of scarce prevention and intervention 
resources.
A unique opportunity for epidemic monitoring within the sub-
Saharan Africa region is the presence of longstanding health 
and demographic surveillance systems (HDSS)19–21. These rou-
tine data collection systems can serve as a vital tool in the public 
health response to Covid-19. HDSS data are typically collected 
through interviews that generate population-representative 
longitudinal cohorts, including information on demograph-
ics (births, deaths, migration), health status and behaviours. 
Historically, they have been conducted in person, however, 
they have increasingly incorporated telephonic or online data 
collection22,23. Additionally, HDSS are well-positioned to evalu-
ate the long-term impacts of the epidemic, by measuring: 
(i) disease penetration through serologic testing; (ii) causes 
of death during and after the epidemic through the use of ver-
bal autopsies24–26; and epidemic impact on economic indicators, 
and non-Covid healthcare access and health outcomes through 
ongoing interviews.
This protocol paper describes the program developed by the 
Africa Health Research Institute (AHRI) to leverage a long-
standing HDSS to perform Covid-19 surveillance in a rural, 
resource-limited setting with very high prevalence of HIV and 
tuberculosis. In this protocol we illustrate how we have lever-
aged existing expertise and population-based surveillance infra-
structure to conduct comprehensive Covid-19 surveillance in 
a rural area without existing surveillance capacity for rapidly 
evolving epidemic disease. We also highlight measures taken to 
minimize Covid-19 transmission risk while conducting this 
research. We provide our methods and surveillance tools as 
potential sources of guidance for others working in similar 
settings.
Protocol
Study aim and objectives
The aims of this study are to conduct active Covid-19 surveil-
lance and to estimate the health and non-health impacts of the 
Covid-19 epidemic in rural South Africa. To achieve these 
aims we will implement longitudinal surveillance based on 
regular telephonic contact with households in a geographically 
defined population. This surveillance will allow us to meet the 
following programmatic and scientific objectives:
a. Support the local public health response by the 
Department of Health (DoH) through screening, 
testing, case notification and linking Covid-19 cases to 
care;
b. Describe the incidence and evolution of Covid-19 
epidemic in a well-defined population in rural KwaZulu-
Natal, including its distribution by age, gender 
and socio-demographic characteristics;
c. Determine the impact of the Covid-19 outbreak and 
non-pharmaceutical control interventions on individual 
behaviour and wellbeing, household socio-economic 
status and health service delivery;
d. Determine the impact of pre-existing health conditions, 
including HIV and tuberculosis on Covid-19 
susceptibility, clinical presentation and outcomes.
Study setting
The study will be conducted within the AHRI Population Inter-
vention Platform surveillance area in the uMkhanyakude 
district of KwaZulu-Natal province. The study area covers 
approximately 850 km2; it is largely rural with one town of 
approximately 30,000 residents, and among the lowest-ranked 
areas in South Africa in terms of socioeconomic status27. A 
large proportion of the population live with HIV (~20% of men 
and ~40% of women aged 15–54 in 201728). Tuberculosis inci-
dence in the district in 2015 was above the national average of 
577 per 100,000 individuals29.
AHRI is a member of the South African Population Research 
Infrastructure Network (SAPRIN), an initiative funded by the 
National Department of Science and Innovation (DSI) and hosted 
by the South African Medical Research Council30. SAPRIN 
standardised the health and demographic surveillance proto-
cols of the three established HDSS sites, in rural KwaZulu-Natal 
(AHRI), Limpopo and Mpumalanga27,30–32. Through SAPRIN, 
the three HDSS sites agreed on a common Covid-19 surveil-
lance protocol, which each node then adapted to its specific 
local health priorities and linkage to care pathways.
Underlying HDSS
Since 2000 AHRI has conducted surveillance of approximately 
20,000 households (totalling over 100,000 resident individuals) 
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to capture births, deaths, migrations and household 
socio-demographics. All households under surveillance are 
contacted once during each 15-week (triannual) surveillance 
cycle. All visits were initially face-to-face, but since 2017, two 
of the three data collection encounters each year have been col-
lected using a telephonic interviewing platform, which allows for 
high-throughput surveillance. These interviews are conducted 
with one household senior representative, acting as proxy for all 
other members. In addition, residents aged 15 years and older 
are invited to participate individually in an annual biobehav-
ioural survey. AHRI has also embedded data collection clerks 
within the eleven public health clinics and one district hospi-
tal serving the study population. These clerks electronically 
capture clinic visits and hospital admissions, and link these 
with the surveillance platform data for all consenting attendees. 
The population database is also routinely linked to the elec-
tronic tuberculosis and HIV treatment registers at these facilities. 
AHRI holds memoranda of understanding with the Provin-
cial and District DoH that permit extraction of health record 
data from primary care and hospital sites for linkage to the 
household surveillance dataset.
Study design
The overall flow of this study is described in Figure 1.
Household questionnaires
This protocol builds upon the underlying routine health and 
demographic surveillance. For the duration of the Covid-19 
lockdown period (and until it is deemed safe by both the South 
African government and study investigators), physical household 
visits have been suspended and replaced by telephonic inter-
views with the household proxy respondent. In addition to the 
standard demographic surveillance questions, proxy respondents 
are asked to answer a Covid-19 questionnaire covering:
a.    A screen for symptoms of Covid-19 for each resident 
household member, completed either by the proxy 
informant or the household member, if available;
Figure 1. Study flow diagram.
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b.    Epidemiologic risk factors for Covid-19 including 
known contacts, healthcare contact, and travel;
c.    Household awareness of Covid-19;
d.    Behaviour changes in response to the epidemic;
e.    Recent visitors to the household and recent travel 
patterns;
f.    Economic and healthcare impacts of Covid-19 
non-pharmaceutical interventions on the household;
g.    Brief mental health assessments of the household 
respondent, using the Patient Health Questionnaire-2 
and Generalized Anxiety Disorder-2 screening tools33,34;
To improve the temporal resolution of Covid-19 surveillance, 
a cohort of 750 households (approximately 3,750 individu-
als) will also be invited to participate in more intensive surveil-
lance, with calls every two weeks, during which all Covid-19 
questions are repeated. The intensive household cohort were 
randomly selected from all households for which at least 
one member also participated in a recent population-wide 
HIV, tuberculosis, and non-communicable disease healthcare 
screening study.
Individual questionnaires
To ensure that detailed information on reaction to the Covid-
19 pandemic is available on the full age-range of residents, 
we will sample 400 past participants in the healthcare screen-
ing study, stratifying by age and gender, and oversampling those 
with multiple non-communicable health conditions. These indi-
viduals will be invited to participate in two-weekly calls to 
report directly on how the epidemic has affected them, includ-
ing detailed descriptions of their travel and direct personal 
contact with others.
Additionally, a qualitative study will gather in-depth informa-
tion from a further sub-sample of the study population. This will 
allow an in-depth understanding of perceptions of risks associ-
ated with Covid-19, and vulnerabilities experienced by the com-
munity. The work will identify contextually appropriate solutions 
to deleterious effects of both Covid-19 epidemic and 
non-pharmaceutical interventions used to mitigate its effects.
Clinical screening of persons under investigation
If a household member screens positive as a potential person 
under investigation (PUI) for Covid-19, based on the current 
South African Covid-19 screening guidelines (see full screen-
ing algorithm in Supplementary Material35), the individual is 
referred to an AHRI Covid-19 mobile testing centre for screen-
ing and a possible diagnostic test. These mobile testing cen-
tres will come to within walking distance of participant homes. 
The testing centres are staffed by AHRI research assist-
ants and senior professional nurses and include strict infec-
tion control and personal protective equipment procedures35. A 
research assistant performs a symptom and epidemiologic screen 
to confirm PUI status. Those meeting PUI criteria are referred 
to a professional nurse who conducts a clinical examination 
for triage, including temperature, respiratory rate, and oxygen 
saturation monitoring. Nurses then complete a testing and refer-
ral questionnaire (see Supplementary Material35) on a tablet 
computer using web-based REDCap forms36. Responses trigger 
assignment to one of the following statuses:
a. PUIs who meet the case definition, and require 
clinical care will undergo Covid-19 testing and 
specimen collection, and then be referred to a local 
Covid-19 treatment facility;
b. PUIs who meet the case definition, but who do not 
require clinical care, will undergo Covid-19 testing and 
specimen collection, and then be referred home for self-
isolation after being given self-isolation and general 
Covid-19 educational materials;
c. Individuals who do not meet the case definition for 
testing and require clinical care will be referred to a 
local health care facility;
d. Individuals who do not meet the case definition and 
do not require clinical care will be sent home with 
Covid-19 information material.
Specimen collection and testing
Specimen collection consists of nasopharyngeal swab and 
oropharyngeal swabs placed together into a cryovial con-
taining 2 ml viral transport medium labelled with a unique 
DataMatrix37 barcode and electronically logged. For young 
children a single nasal mid-turbinate swab (collected from both 
nostrils) will replace the nasopharyngeal and oropharyngeal 
swabs. Specimens will be stored and shipped at 2–8°C to the 
AHRI Diagnostic Laboratory in Durban within 24 hours of sample 
collection, for processing and testing.
On receipt in the AHRI Diagnostic Laboratory, the specimens 
will be registered and tracked on the Laboratory Information 
Management system (LIMS)38 and undergo inactivation (at 60°C 
for 30 minutes). Following inactivation, extraction will be per-
formed either manually using the QIAamp® Viral RNA kit 
(Qiagen, Germany) or on the ChemagicTM 360 Nucleic Acid 
Extractor (Perkin Elmer, Waltham, MA, USA) using ChemagicTM 
Viral DNA/RNA 300 Kit H96 (Perkin Elmer, Waltham, MA, 
USA). SARS-CoV-2 templates will be generated using the 
TaqManTM 2019-nCoV Assay Kit v1 or v2 (Applied Biosys-
tems, Foster City, CA, USA) and run on The Applied Bio-
systems QuantStudio 5 or 7 Real-Time PCR System by the 
KwaZulu-Natal Research Innovation and Sequencing Platform 
(KRISP) or by AHRI on a CFXTM Touch Real-Time System 
(Bio-Rad (Hercules, CA, USA) or Abbott m2000rt).
We will use comparative Ct to analyse 2019-nCoV assay 
data, with Ct <37 regarded as positive (CoV-2 RNA detected), 
Ct ≥37 but <40 considered indeterminate, and Ct ≥40 as nega-
tive. Indeterminate results will be repeated from the amplifi-
cation process and if found to be indeterminate, the sample 
re-extracted and amplified; if the sample remains indeterminate 
it will be reported as suspected positive/positive. Positive cases 
with a Ct <20 will be genotyped using the ARTIC network 
SARS-CoV-2 whole genome sequencing (WGS) protocol at 
KRISP39. WGS will be assembled using Genome Detective40 
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and analysed using phylogenetic software applications, such as 
BEAST41 and Nextstrain42. All genomes will be analysed with 
over 12,000 WGS publicly available in the GISAID database43.
Results reporting and disease monitoring
The SARS-CoV-2 test results will be electronically trans-
ferred to the study database and presented for clinical review to 
the study physician.
a. PUIs testing negative for SARS-CoV-2 will be informed 
of their results via short message service (SMS);
b. PUIs testing positive for SARS-CoV-2 will be called 
by a study physician to be informed of their results. 
Covid-19 cases will be followed longitudinally with 
phone calls every three days for clinical monitoring 
until resolution of symptoms. Those with worsening 
symptoms will be referred to the AHRI mobile testing 
centre for further attention and, if warranted, referral to 
the regional Covid-19 treatment centre.
All Covid-19 test results will be submitted to the national notifi-
able medical conditions web portal; a system-generated PUI 
(including a contacts list) form will also be submitted to the 
local public health service.
After the Covid-19 outbreak and upon resumption of the par-
ent AHRI surveillance protocol, which provides for an annual 
dried blood spot collection from resident individuals age 15 
years and above, the protocol provides for measurement of 
SARS-CoV-2 seroprevalence, which will be conducted to deter-
mine contributions of asymptomatic disease to the epidemic.
All participants with positive COVID-19 test results will be con-
sidered for enrolment in a related study titled, “Consequences 
of HIV and TB Co-Infection on COVID-19 Disease Dynamics, 
Severity and Immune Responses,” which is a longitudinal dis-
ease characterization and sample collection protocol to establish 
mechanistic interactions between HIV, TB and COVID-19.
Data analysis and sample size
We will collect and report Covid-19 surveillance data in real-
time to local partners, including the DoH and the AHRI Com-
munity Advisory Board. At the conclusion of each week, 
we will report the following indicators to key stakeholders:
1. Number of households screened by phone call;
2. Number of individuals screened (through proxy);
3. Proportion of households contacted and consented;
4. Proportion of households and individuals with a 
positive case definition screen;
5. Number of PUI screened at Covid-19 clinics;
6. Number of Covid-19 tests conducted;
7. Number and proportion of Covid-19 tests resulting 
positive;
8. Number of individuals referred to clinic for moderate/
severe Covid-19 disease;
9. Population-representative prevalence of Covid-19 
overall and by age and sex.
At the conclusion of each 15-week surveillance block, we will 
additionally conduct a total population Covid-19 epidemio-
logic summary, including age, sex, and HIV-serostatus stratified 
Covid-19 prevalence and prevalence of moderate/severe disease. 
This project is designed to conduct surveillance of the entire 
HDSS population area and thus is not powered to test a spe-
cific hypothesis. However, with a total population sample size 
of 100,000, and assuming 60% participation in each 15-week 
block from at least one household member, we will have substan-
tial power to estimate overall and stratified Covid-19 prevalence 
estimates within age and sex strata (Table 1).
Data management. Data collected in this study will be centrally 
stored on AHRI’s secure data servers. Data will be collected 
through interviews at the call centre on central server using Sur-
vey Solutions44, and in the field on encrypted tablet computers 
Table 1. The 95% confidence intervals for prevalence estimates for surveillance platform based on sub-group and 
total population prevalence of 1 and 5%.
Sex Age Band Population Size 95% confidence interval for 1% prevalence*
95% confidence interval for 5% 
prevalence*
Female <19 years 21,922 0.87 – 1.11% 4.71 – 5.29%
Male <19 years 22,041 0.87 – 1.13% 4.71 – 5.30%
Female 20–49 
years
23,853 0.87 – 1.13% 4.73 – 5.29%
Male 20–49 
years
17,220 0.86 – 1.16% 4.67 – 5.33%
Female >49 years 11,241 0.82 – 1.20% 4.60 – 5.42%
Male >49 years 4,958 0.75 – 1.33% 4.41 – 5.64%
Total Pop -- 101,235 0.94 – 1.06% 4.87 – 5.13%
*Confidence intervals estimated with the exact method to account for small proportion sizes.
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using REDCap, and then securely uploaded to a central server. 
Collected specimens will be logged on CRF system and control 
lists generated to verify that all specimens have arrived at the 
laboratory. These lists will be electronically transferred to LIMS. 
An electronic study dashboard will assist operational teams in 
monitoring study progress. Database rules and constraints will be 
enforced on the master database to ensure that only valid data is 
stored. Personally identifiable data will be restricted to separate 
database tables accessible only to data management staff – these 
will never be shared with the research team.
Risks and benefits for participants
The protocol adheres to the provisions of the Covid-19-specific 
National Infection Prevention and Control Strategic Framework45, 
as well as research conduct guidance by national and interna-
tional research oversight bodies. The main risk to study activi-
ties and participation is of SARS-CoV-2 transmission from 
in-person interactions between staff and study participants 
(i.e., at testing centres). Following a risk assessment35, we have 
implemented multiple control measures to minimize this risk, 
including: physical barriers; physical distancing; regular hand 
hygiene; and careful training on and use of standard operat-
ing procedures. Should it become impossible to comply with 
these provisions due to personal protective equipment sup-
ply shortages, case load, or other unforeseen challenges, 
surveillance will be paused, scaled back or terminated.
Consent and assent
This protocol builds on the consent procedures in place for the 
household surveillance protocol it is embedded in. All house-
holds contacted for this study have previously provided written 
consent to: (i) be approached via a telephone call to be asked to 
participate in research studies; (ii) electronic linkage of sur-
veillance study records with their medical records; and (iii) the 
sharing of anonymized data in data repositories accessible 
to the broader scientific community.
In this study, all participants are asked to provide verbal 
informed consent35 prior to telephone interviews, which will be 
recorded in accordance with Covid-19 specific guidance from 
the University of KwaZulu-Natal Biomedical Research Ethics 
Committee46. Additionally, verbal consent for specimen col-
lection and testing will be obtained (and recorded on the elec-
tronic case form) at the specimen collection point. Verbal 
recording of consent will remove the danger of transmitting 
SARS-COV-2 via the data collection tablet or a stylus. Any 
potential participants aged under 18 and not emancipated will 
be asked to provide recorded verbal assent after a responsible 
adult has provided informed consent.
Community engagement
The protocol was presented to both the DoH and the AHRI 
Community Advisory Board management committee and 
approved by both prior to submission for ethical approval. Bulk 
SMS messages are used to communicate Covid-19 informa-
tion and study specific arrangements to the research population. 
Local radio stations will broadcast information on the study 
and feature interviews with study staff.
Ethical approval
The protocol received ethical approval from the University of 
KwaZulu-Natal Biomedical Research Ethics Committee on 
2 April 2020 under reference BE290/16 and from the KwaZulu 
DoH Research Committee.
Dissemination policy
The key findings of this study will be prepared for dissemina-
tion as rapidly as possible, given the urgency of the Covid-19 
epidemic. These will be provided to the DSI and other gov-
ernment decision-makers at national and provincial levels, 
including the provincial DoH. They will also be submitted to 
open-access pre-print servers and as open-access articles to 
peer-reviewed journals.
Study limitations
One limitation is the possibility of not re-interviewing the partici-
pant in the next round. On average, 12.0% (range 5.7%–16.9%) 
of HDSS participants are not re-interviewed the next year due 
to out migration, death, loss to follow-up or refusal. Over 80% 
of these losses are due to outmigration; however, 80% of these 
outmigrants remain household members, and are therefore 
accessible to collect outcome data. Additionally, for an acute 
infection with a relatively short symptom duration, the 15 weeks 
between surveillance contacts means that some proportion 
of cases will be missed. This limitation is mitigated to some 
extent by the two-weekly surveillance of 750 households, but 
the analytical power of this cohort will depend on the cumu-
lative incidence of Covid-19 in the overall study population. 
Moreover, our study depends on symptomatic screening and 
proxy responses by heads of households, which will also be 
susceptible to under-reporting47–49. Proxy-based case identifica-
tion will be augmented by documentation of cases from the study 
community presenting at the eleven primary health care clinics 
and one district hospital in the population study catchment area. 
Our ability to conduct a post-outbreak seroprevalence study 
will allow for detection of missed cases in this surveillance pro-
gram, and ultimately serve a complementary role in epidemic 
description in this population.
Discussion
Widespread SARS-CoV-2 testing for surveillance and case iden-
tification has been established as a major priority in the epi-
demic response. Although testing capacity has been limited in 
many areas of the world, HDSS provide a pre-existing structure 
in resource-limited settings that is purpose-built for surveil-
lance, with both expertise and infrastructure for conducting 
population-based surveys.
We have leveraged a HDSS to develop and implement a Covid-19 
surveillance program in rural South Africa. In doing so, we 
focused on the following major considerations to ensure both 
optimal scientific methods and the safety of our staff and 
study population:
1. Total-population sampling, with enhanced surveillance 
of random sub-samples for early identification of high 
transmission areas and groups;
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2. Phone-based screening surveillance to minimize 
in-person contact;
3. Limiting all in-person interactions to persons under 
investigation;
4. Strict adherence to personal protective equipment 
use, well-trained staff using standardized operating 
procedures and risk mitigation plans, and hygiene 
measures in line with national and international 
guidelines;
5. Laboratory procedure conducted in a clinical research 
laboratory within good laboratory clinical practice 
guidelines;
6. Partnership with DoH and other government 
departments for case detection, reporting, contact tracing 
and to ensure all procedures fall within governmental 
guidance;
7. Real-time reporting of surveillance results to inform 
epidemic response and resource allocation.
Herein we report the details of our cohort design, question-
naires, data and reporting structures, and standard operating 
procedures in hopes that our project can be used to hel 
inform other similar programs elsewhere in the region.
Future data availability
A core set of the Covid-19 surveillance indicators and data will 
made available for the three SAPRIN nodes in the publicly 
accessible SAPRIN data repository (http://saprindata.samrc.
ac.za/index.php/catalog). AHRI-specific data will be dissemi-
nated through the AHRI data repository (https://data.africacentre.
ac.za/) within six months from the conclusion of the first 15-week 
surveillance cycle. Both datasets will be linkable to existing core 
demographic surveillance data.
Data availability
Underlying data
No underlying data are associated with this article.
Extended data
Zenodo: Protocol: Leveraging a demographic and health 
surveillance system for Covid-19 Surveillance in rural 
KwaZulu-Natal Supplementary Material. https://doi.org/10.5281/
zenodo.383793135
This project contains the following extended data:
• Suppl Mat 1.docx (South African national Covid-19 
screening algorithm)
• Suppl Mat 2.docx (Standard Operating Procedures)
• Suppl Mat 3.docx (Questionnaires)
• Suppl Mat 4.docx (Risk Assessment)
• Suppl Mat 5.docx (Informed consent wording)
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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